ICH S7A Safety Pharmacology: Core Battery Requirements

Safety pharmacology is the part of the IND that should be easy. Compared to interpreting immunotoxicity data in transgenic models or arguing about species relevance for a bispecific antibody, the core battery is almost comfortingly straightforward: does the drug mess with the heart, the lungs, or the brain? Three organ systems. A handful of studies. Well-established protocols.

And yet. This is where I've seen programs that were otherwise beautifully designed — rigorous tox, clean PK, thoughtful species selection — fall apart over a $30K assay that nobody scheduled. The requirements are specific, GLP is non-negotiable, and the cost of a clinical hold dwarfs the cost of doing it right.

ICH S7A defines the core battery. ICH S7B adds cardiac safety. Together they govern the safety pharmacology section of your IND.

What the core battery covers

ICH S7A requires assessment of drug effects on three vital organ systems: cardiovascular, respiratory, and central nervous system. The concept is simple — before you dose humans, verify that the drug doesn't cause acute, life-threatening effects on the organs that keep people alive.

The core battery is separate from general toxicology. Yes, your repeat-dose toxicity studies will collect some of the same endpoints (blood pressure, heart rate, clinical observations). But the safety pharmacology core battery is designed specifically to detect functional effects on vital organ systems at and above the therapeutic exposure range. Different purpose, different study design.

Cardiovascular assessment

This is the most complex — and the most consequential — component of the core battery. Cardiovascular safety pharmacology has two main elements:

1. The hERG assay (ICH S7B)

The human Ether-a-go-go Related Gene (hERG) encodes the cardiac potassium channel responsible for the rapid component of the delayed rectifier potassium current (IKr). Block this channel and you prolong the QT interval on an ECG. Prolong QT enough and you get torsades de pointes — a potentially fatal ventricular arrhythmia.

The hERG assay is an in vitro electrophysiology study. HEK293 or CHO cells expressing the hERG channel are patch-clamped, exposed to your drug at multiple concentrations, and the effect on IKr current is measured. You get an IC50 — the concentration at which 50% of the current is inhibited.

The safety margin that matters: the ratio of the hERG IC50 to the expected free (unbound) plasma concentration at the maximum clinical dose. FDA and ICH don't specify a hard cutoff, but industry convention treats a margin of <30x as a potential concern. Below 10x, you have a problem.

The GLP trap I've mentioned before but will repeat because it keeps happening: Companies run a non-GLP hERG assay during lead optimization to inform compound selection. Clean result. They then include this non-GLP data in the IND as their cardiac safety assessment. FDA rejects it. The study must be conducted under GLP (21 CFR Part 58) to be acceptable as pivotal safety data. The non-GLP result is useful as supportive data, but you still need a GLP-compliant study.

A GLP hERG study costs $30-50K and takes 4-6 weeks. Compared to the 6-12 month delay of a clinical hold, it's cheap insurance.

2. In vivo cardiovascular telemetry (ICH S7A + S7B)

The in vivo cardiovascular study — typically conducted in conscious, telemetered dogs (beagle) or non-human primates — measures blood pressure, heart rate, and ECG parameters (including QT/QTc interval) after drug administration.

Study design considerations:

• Species: Usually dog for small molecules. NHP for biologics that don't cross-react in dogs. The species should match or be relevant to your toxicology species.
• Doses: At least 3 dose levels, with the high dose targeting multiples of the expected therapeutic exposure. Include a vehicle control group.
• Duration: Single-dose administration with at least 24 hours of continuous telemetry recording. Some protocols extend to 48 hours for drugs with long half-lives.
• Parameters: Systolic and diastolic blood pressure, mean arterial pressure, heart rate, PR interval, QRS duration, QT interval, QTc (corrected for heart rate).
• GLP compliance: Required for IND submission.

This study typically costs $150-300K depending on species (NHP is more expensive), group sizes, and CRO. Timeline: 3-6 months including study scheduling, in-life phase, and report writing.

ICH S7B update (2022): The revised S7B guideline introduced the concept of a nonclinical "best practices" approach to proarrhythmic risk assessment. This includes the option to use in silico models (in particular, the CiPA — Comprehensive in Vitro Proarrhythmia Assay — initiative) to integrate data from multiple ion channel assays and computational modeling. The approach is gaining acceptance, but the conventional hERG + in vivo telemetry combination remains the standard that FDA reviewers are most comfortable with.

Respiratory assessment

Respiratory function testing per ICH S7A evaluates the drug's effect on tidal volume, respiratory rate, and minute ventilation. The standard method is whole-body plethysmography in conscious rodents (typically rats).

Study design:

• Species: Rat (usually Sprague-Dawley)
• Doses: At least 3 dose levels plus vehicle control
• Parameters: Tidal volume (TV), respiratory rate (f), minute ventilation (MV = TV x f). Some protocols add enhanced pause (Penh), though its physiological significance is debated.
• Duration: Measurements at baseline and multiple timepoints after dosing, covering the expected Tmax and at least 4 hours post-dose
• GLP: Required

This study is relatively inexpensive ($40-80K) and fast (2-4 months including report). The science is straightforward — you're measuring whether the drug depresses breathing.

Common pitfall: insufficient dose range. If your highest dose doesn't produce any respiratory effects, great — but FDA may ask whether you tested high enough. The high dose should be at least 2-4x the expected human exposure, or a dose that produces some pharmacological or toxicological effect, whichever is lower.

CNS assessment

Central nervous system safety pharmacology is the most variable of the three core battery components. ICH S7A specifies assessment of motor activity, behavioral changes, coordination, sensory/motor reflex responses, and body temperature.

The two main approaches:

1. Modified Irwin test / functional observational battery (FOB): A systematic observation of the animal in a structured environment, scoring parameters like arousal, gait, posture, muscle tone, reflexes, pupil size, salivation, lacrimation. This is typically done in rats at multiple timepoints after dosing.

2. Locomotor activity: Automated measurement of spontaneous motor activity in rats placed in an activity monitoring chamber. Quantitative and objective, but only captures one dimension of CNS function.

Most programs combine both — FOB plus locomotor activity in the same animals. This gives you qualitative (behavioral observations) and quantitative (activity counts) data.

Study design:

• Species: Rat
• Doses: At least 3 dose levels plus vehicle
• Parameters: FOB (30+ endpoints), locomotor activity
• Duration: Baseline, multiple post-dose timepoints (at least through expected Tmax and 24 hours post-dose)
• GLP: Required

Cost: $50-100K. Timeline: 2-4 months.

Study timing

The core battery must be completed before the first human dose. Per ICH M3(R2), the safety pharmacology core battery is a required component of the Phase 1-enabling nonclinical package.

Some companies try to integrate safety pharmacology endpoints into their general toxicology studies to save time and money. ICH S7A permits this "integrated" approach in principle, but with conditions:

• The study must be specifically designed to evaluate the safety pharmacology endpoints (not just incidentally collecting cardiovascular data during a tox study)
• Sensitivity must be adequate — group sizes and observation periods must be sufficient to detect pharmacologically meaningful effects
• The study must be GLP-compliant for the safety pharmacology assessments

In practice, integrating cardiovascular telemetry into a dog tox study is common and accepted. The dogs are already surgically implanted with telemetry transmitters for the tox study; extending the telemetry recording to capture safety pharmacology endpoints is logistically straightforward.

Integrating respiratory and CNS endpoints into rat tox studies is more problematic, because the group sizes and study designs for standard tox studies aren't always optimized for these assessments. My recommendation: run standalone respiratory and CNS studies unless your CRO has a validated integrated protocol that FDA has previously accepted.

Supplementary studies

Beyond the core battery, ICH S7A defines supplementary studies that may be needed based on the drug's pharmacological profile or findings from the core battery:

• Gastrointestinal function: Transit, secretion, gastric pH. Relevant for drugs that target GI receptors or have GI side effects in animals.
• Renal function: Urine volume, electrolytes, pH, osmolality. For drugs with renal pharmacology or nephrotoxic potential.
• Autonomic nervous system: Cardiovascular responses to autonomic challenges. If your core battery cardiovascular study shows equivocal results.
• Additional CNS: Cognitive function, seizure threshold, dependence/abuse liability. For drugs targeting CNS receptors.

Supplementary studies are triggered by signals, not required by default. If your core battery is clean and there's no pharmacological basis for concern in a specific organ system, supplementary studies aren't needed. But if the hERG assay shows a marginal safety margin, or the FOB shows behavioral changes at clinically relevant exposures, FDA will want supplementary data.

What goes in the IND

Your safety pharmacology data goes in two places:

1. Module 4.2.1.3 — Safety pharmacology study reports. Individual study reports for each core battery study.
2. Module 2.6.2 — Pharmacology written summary. Integrated narrative summarizing all pharmacology studies (primary, secondary, and safety pharmacology).

In the written summary, present the safety pharmacology findings in the context of expected human exposure. A hERG IC50 means nothing without comparison to the anticipated free plasma concentration at the clinical dose. A telemetry finding at 100 mg/kg in dogs is interpreted differently if the expected human dose is 1 mg/kg vs. 50 mg/kg. Exposure margins are the language FDA reviewers speak.

Common deficiencies

Incomplete core battery. I've reviewed INDs where the cardiovascular assessment was thorough (hERG + telemetry) but the respiratory and CNS studies were missing or relegated to "observations in the general tox study" without explicit safety pharmacology design. FDA flags this. The core battery is three components, not one.

Non-GLP hERG submitted as pivotal. I'll say it one more time. GLP. Always. For the pivotal hERG.

Inadequate exposure margins. The high dose in your safety pharmacology studies should achieve systemic exposure that provides a meaningful safety margin over the expected human exposure. If the highest dose tested is only 2x the human equivalent, FDA may ask for higher-dose data. Target at least 10-20x the expected clinical exposure at the high dose, or a dose that produces maximal tolerated effect.

Missing ECG waveform analysis. Some cardiovascular telemetry studies report only heart rate and blood pressure, omitting the detailed ECG interval analysis (PR, QRS, QT/QTc). The ECG parameters are the whole point of the in vivo study — they complement the hERG data and provide a complete picture of cardiac electrical activity.

Late study execution. Safety pharmacology studies have surprisingly long timelines when you factor in CRO scheduling, surgical implantation recovery (for telemetry), in-life phase, data analysis, and report writing. A cardiovascular telemetry study can take 4-6 months from protocol initiation to final report. Don't leave it until the end of your IND-enabling program.

I'll be honest about something: when I first started reviewing safety pharmacology packages, I thought the core battery was over-specified. Three separate study types, all GLP, for what's essentially a screening exercise? Then I read about terfenadine. An antihistamine that was on the market for years before anyone connected it to fatal cardiac arrhythmias via hERG channel blockade. It was withdrawn in 1998. The entire modern safety pharmacology framework — S7A, S7B, the hERG assay as a standard screening tool — exists in part because of that drug. The requirements aren't arbitrary. They're scar tissue from a catastrophic failure in a system that didn't require these tests.

Cost and timeline summary

Running the three in vivo studies in parallel, the core battery takes about 4-6 months. This should be one of the first things you schedule when you decide to pursue an IND — it's not on the critical path if you start early, but it becomes the critical path if you start late.

---

Related reading:

• FDA IND Submission Checklist 2026 — where safety pharmacology fits in the IND
• ICH S2 Genotoxicity Testing Guide — the other core battery
• 5 Most Common IND Deficiencies — safety pharmacology gaps rank high

If you're assembling your safety pharmacology package and want to check it against S7A/S7B requirements before filing, RegFo runs the gap analysis and cites the specific guideline sections. Three minutes, not three weeks.